The incidence of cardiac surgeries is increasing world-wide in view of the demographic change. Cardiac surgery carries a significant amount of risk as on average 60% of patients develop postoperative atrial fibrillation, by far the most frequently occurring complication after cardiac surgery. Clinical investigations show a significant increase in morbidity, mortality and duration of treatment and hospital stay. The risk for stroke is increased 3-fold! From all discussions with renowned surgeons results the clear statement that an avoiding or reduction of medical drugs is in any circumstance a preferable and desirable ambition. The DefiPace™ system is a proven and awaited method by the physicians treating post-operative patients. Our new system is unique, as it is the only system in history and today, which allows physicians to prevent and terminate postoperative atrial fibrillation (POAF) in all patients. It is the only system which combines standard stimulation, bi-atrial pacing as well as epicardial low-energy cardioversion in one hand-held easy-to-use device even on general ward. Target customers are all patients undergoing cardiac surgery world-wide (market volume: € 1.5 billion). Advantages: Simplicity • TMA pacing & cardioversion wires: easy to use, similar to standard pacing wires • DefiPace device: Intuitive handling for clinical staff similar to standard external pacemakers Prevention and Termination: • Bi-atrial pacing as an effective way to prevent POAF • Quick Termination of atrial fibrillation with safe, elegant low energy cardioversion • No anesthesia necessary Cost savings for surgical clinics • Significant cost savings: at least €1,000per day/patient Improved health • Few or no medication required • All complications from atrial fibrillation can be completely avoided The DefiPace™-System is as a key product for OSYPKA and will lead to significant increase of sales and employees. We will revolutionize the pacemaker market a second time in our history

In patients undergoing open-heart surgeries, perioperative cardiac monitoring is used to track the functioning of the heart and identify complications. However, myocardial failure and other severe complications can escape detection using current monitoring technologies, given the trade-offs between invasiveness, real time measurements, accessibility and accuracy of data. Given the high-risk profile of these surgeries, failure to timely detect complications leads to increased mortality and morbidity, which in turn results in increased hospitalization costs and lower quality of life for the affected patients. For effective cardiac monitoring, surgeons need real time data, 24h continuous monitoring during and post-surgery, and an accurate biosignal marker that can be trusted for immediate detection and assessment of cardiac events. No current technology enables this with low invasiveness and risk. Cardiaccs (SME) and Osypka (SME) will bring to market a patented solution that involves adding a 3-axis accelerometer to a standard epicardial pace lead, which is routinely used for most cardiac surgical patients, to assess cardiac motion and contractility in real time, both during and after surgery – and up to 7 days. Data from CardiSense will appear on a monitor and an alert function will let surgeons and nurses know as soon as a complication is picked-up on the continuously analysed data. SAMBAfun brings together 2 SMEs with complementary know-how, IPR and value chain positions. Cardiaccs patented the concept, whereas Osypka has 40 years of experience in developing cardiac pace leads. Osypka dominates the German market and has extensive ties to global distributors. Three leading research hospitals (Oslo, Aarhus and Berlin) will demonstrate the latest advances in this device, provide Key Opinion Leader input and contribute with multi-market, highly credible data for regulatory certification and health economic models to support reimbursement applications in all markets.

The strong drive for more complex systems and more advanced packaging, including optics and photonics, creates a chance to retain the manufacturing and packaging value chain to Europe - or even start to bring it back. APPLAUSE supports this by building on the European expertise in advanced packaging and assembly to develop new tools, methods and processes for high volume mass manufacturing of electrical and optical components. The technologies will be piloted in 5 industrial Use Cases, related to 1. Substantially smaller 3D integrated ambient light sensor for mobile and wearable applications (AMS) 2. High performance, low cost, uncooled thermal IR sensor for automotive and surveillance applications (IDEAS) 3. High speed Datacom transceivers with reduced manufacturing costs (DustPhotonics) 4. Flexible cardiac monitoring patch and miniaturized cardiac implants with advanced monitoring capabilities (GE Healthcare and Cardiaccs). The APPLAUSE consortium is built of a number of leading experts from European electronics packaging companies representing different value chain levels related to advanced packaging and smart system integration. The parties have complementary expertise in conception, design, packaging, testing and manufacturing of electronic components, as well as a wide range of expertise from several different end use areas. The unique European ecosystem established within the consortium represents the competitive, leading edge of the technologies available.

The goal of the InForMed project is to establish an integrated pilot line for medical devices. The pilot line includes micro-fabrication, assembly and even the fabrication of smart catheters. The heart of this chain is the micro-fabrication and assembly facility of Philips Innovation Services, which will be qualified for small/medium-scale production of medical devices. The pilot facility will be open to other users for pilot production and product validation. It is the aim of the pilot line: to safeguard and consolidate Europe’s strong position in “traditional” medical diagnostic equipment, to enable emerging markets - especially in smart minimally invasive instruments and point-of-care diagnostic equipment - and to stimulate the development of entirely new markets, by providing an industrial micro-fabrication and assembly facility where new materials can be processed and assembled. The pilot line will be integrated in a complete innovation value chain from technology concept to high-volume production and system qualification. Protocols will be developed to ensure an efficient technology transfer between the different links in the value chain. Six challenging demonstrators products will be realized that address societal challenges in: “Hospital and Heuristic Care” and “Home care and well-being,” and demonstrate the trend towards “Smart Health” solutions.